Zymeworks Inc Common Stock

Yahoo Finance • 3 days ago

Three Companies Estimated To Be Trading Below Their Intrinsic Value

As the U.S. stock market continues to reach new heights, with major indices like the S&P 500 setting all-time records, investors are increasingly looking for opportunities that may be overlooked in this bullish environment. In such a clima... Full story

Yahoo Finance • 4 days ago

3 Stocks Estimated To Be Trading At Discounts Of 23.1% To 41.2%

In a robust market environment where the Dow Jones and S&P 500 have recently set new records, investors are keenly observing opportunities that may be overlooked amid widespread gains. Identifying undervalued stocks can be particularly rew... Full story

Yahoo Finance • 10 days ago

3 Stocks Estimated To Trade At Discounts Of Up To 49.7%

As the U.S. stock market experiences a notable downturn, with major indexes like the S&P 500 and Dow Jones Industrial Average posting consecutive losses amid tech sector retreats and AI bubble concerns, investors are increasingly on the lo... Full story

Yahoo Finance • 26 days ago

Zymeworks Announces Participation in Upcoming Conferences

• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-t... Full story

Yahoo Finance • last month

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biothe... Full story

Yahoo Finance • last month

Zymeworks shifts to a royalty-driven business model

[Golden Percentage Symbol] fatido Zymeworks (ZYME [https://seekingalpha.com/symbol/ZYME]) on Tuesday announced plans to focus on a royalty-driven growth model backed by its internal R&D engine and licensing arrangements with companies suc... Full story

Yahoo Finance • last month

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

MarketNewsUpdatesNews Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer focus on preventive and longevity-focu... Full story

Yahoo Finance • last month

Zymeworks Appoints Scott Platshon Acting Chief Investment Officer

(RTTNews) - Zymeworks Inc. (ZYME), a Canadian biotechnology company, Tuesday said that it has appointed Scott Platshon as Acting Chief Investment Officer. The company said that Platshon will directly report to Chair and Chief Executive Of... Full story

Yahoo Finance • last month

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional bioth... Full story

Yahoo Finance • last month

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholdersStrategic initiative follows positive topline results from pivotal Phase 3 HERIZON-GEA-01 trial evaluating... Full story

Yahoo Finance • last month

Key Catalysts Emerge in Oncology, Synthetic Biology, and M&A Activity as Markets Open

DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Markets open this morning with a distinctly biotech-heavy narrative delivering milestone developments. Zymeworks and Jazz Drop Landmark Phase 3 Data: Ziihera Positioned as New HER2 Standard in F... Full story

Yahoo Finance • last month

Stocks making the biggest moves premarket: Alphabet, Zymeworks, lithium producers, Quantum Computing, Clearwater Analytics and more

Check out the companies making headlines in premarket trading. Alphabet — The YouTube and Google owner rose more than 4% after Warren Buffett's Berkshire Hathaway revealed it took a more than $4 billion stake in Alphabet in the third quart... Full story

Yahoo Finance • last month

Jazz, Zymeworks’ Ziihera trial shows significant PFS improvement, shares rally

[Biomedical Researchers Conduct Experiments in a Modern Laboratory. Female Scientist Preparing a Set of Samples in Test Tubes with Purple Caps. Colleague Analyzes Data on a Computer in the Background] gorodenkoff/iStock via Getty Images... Full story

Yahoo Finance • last month

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS a... Full story

Yahoo Finance • 2 months ago

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story

Yahoo Finance • 3 months ago

Will Zymeworks’ (ZYME) New R&D Leadership Mark a Turning Point in Its Oncology Strategy?

Zymeworks Inc. recently appointed Adam Schayowitz, Ph.D., MBA, as Acting Chief Development Officer to accelerate its pipeline and partnership integration, leveraging his nearly 20 years of oncology drug development experience. Dr. Schayowi... Full story

Yahoo Finance • 3 months ago

Bitcoin Miner Leads Two Health Care Stocks To New Highs

Core Scientific hit an all-time high in Friday's stock market. Shares are on a three-day winning streak and just above a cup base's buy point of 18.21, making the company one that's reaching new highs and worth watching. Its relative stren... Full story

Yahoo Finance • 3 months ago

Align downgraded, NetEase upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: JPMorgan upgraded NetEase (NTES) to Ov... Full story

Yahoo Finance • 3 months ago

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story

Yahoo Finance • 4 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 0.2% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story